ebomi
Colour theme
Sign in
Insider · CIK 0001249675

Perceptive Life Sciences Master Fund Ltd

CIK 0001249675 Name as filed on the most recent filing

Filed as Perceptive Life Sciences Master Fund Ltd (318)

817 transaction lines · from 318 filings · filed 2003-08-08 to 2025-11-13 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised. The 40 most recent are shown; the catalog may hold more for this insider.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2021-05-24 P, Open-market purchase Nautilus Biotechnology, Inc.NAUT 70,983, acquired Open Form 4 filing 0001062993-21-005576
2021-05-20 P, Open-market purchase Arya Sciences Acquisition Corp IIIARYA 1,607,246, acquired Open Form 4 filing 0001062993-21-005014
2021-05-06 S, Open-market sale Vyne Therapeutics Inc.VYNE 3,670,000, disposed Open Form 4 filing 0001062993-21-004265
2021-05-03 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 15,000,000, acquired Open Form 4 filing 0001062993-21-004109
2021-04-27 P, Open-market purchase Rain Therapeutics Inc.RAIN 9,350,000, acquired Open Form 4 filing 0001062993-21-003864
2021-04-08 P, Open-market purchase Crinetics Pharmaceuticals, Inc.CRNX 4,999,996, acquired Open Form 4 filing 0000899243-21-015456
2021-03-23 P, Open-market purchase Solid Biosciences Inc.SLDB 14,999,996, acquired Open Form 4 filing 0001062993-21-002952
2021-03-16 P, Open-market purchase Prometheus Biosciences, Inc.RXDX 16,150,000, acquired Open Form 4 filing 0001062993-21-002765
2021-02-09 P, Open-market purchase Landos Biopharma, Inc.LABP 2 lines 1,403,559, acquired Open Form 4 filing 0001062993-21-001115
2021-02-08 P, Open-market purchase Landos Biopharma, Inc.LABP 20,000,000, acquired Open Form 4 filing 0001062993-21-001012
2021-02-08 P, Open-market purchase Landos Biopharma, Inc.LABP 3 lines 1,503,061, acquired Open Form 4 filing 0001062993-21-001115
2021-02-05 P, Open-market purchase Landos Biopharma, Inc.LABP 305,826, acquired Open Form 4 filing 0001062993-21-001115
2021-01-28 P, Open-market purchase Vyne Therapeutics Inc.VYNE 9,999,999, acquired Open Form 4 filing 0001062993-21-000765
2021-01-25 P, Open-market purchase Athira Pharma, Inc.ATHA 6,999,998, acquired Open Form 4 filing 0001062993-21-000660
2021-01-22 S, Open-market sale Scynexis IncSCYX 2 lines 2,629,781, disposed Open Form 4 filing 0000899243-21-003426
2021-01-22 S, Open-market sale Motus GI Holdings, Inc.MOTS 814,000, disposed Open Form 4 filing 0000899243-21-003066
2021-01-21 S, Open-market sale Scynexis IncSCYX 701,100, disposed Open Form 4 filing 0000899243-21-003426
2021-01-21 S, Open-market sale Motus GI Holdings, Inc.MOTS 1,132,911, disposed Open Form 4 filing 0000899243-21-003066
2021-01-20 S, Open-market sale Scynexis IncSCYX 1,374,550, disposed Open Form 4 filing 0000899243-21-003426
2021-01-20 S, Open-market sale Motus GI Holdings, Inc.MOTS 586,166, disposed Open Form 4 filing 0000899243-21-003066
2021-01-19 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 13,000,000, acquired Open Form 4 filing 0001062993-21-000506
2021-01-08 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 3 lines 5,137,668, acquired Open Form 4 filing 0001062993-21-000275
2021-01-07 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 4,065,000, acquired Open Form 4 filing 0001062993-21-000275
2020-11-23 P, Open-market purchase MeiraGTx Holdings plcMGTX 6,425,000, acquired Open Form 4 filing 0000899243-20-032016
2020-10-27 P, Open-market purchase Cerevel Therapeutics Holdings, Inc.CERE 30,000,000, acquired Open Form 4 filing 0000899243-20-029743
2020-10-21 P, Open-market purchase Arya Sciences Acquisition Corp IIARYB 435,838, acquired Open Form 4 filing 0000899243-20-029111
2020-10-20 P, Open-market purchase Arya Sciences Acquisition Corp IIARYB 1,141,000, acquired Open Form 4 filing 0000899243-20-029111
2020-09-22 P, Open-market purchase Athira Pharma, Inc.ATHA 18,000,008, acquired Open Form 4 filing 0000899243-20-025964
2020-09-15 P, Open-market purchase Quotient LtdQTNT 12,374,997, acquired Open Form 4 filing 0000899243-20-025269
2020-09-14 P, Open-market purchase Athenex, Inc.ATNX 19,800,000, acquired Open Form 4 filing 0000899243-20-024976
2020-09-14 P, Open-market purchase Albireo Pharma, Inc.ALBO 16,000,000, acquired Open Form 4 filing 0000899243-20-025069
2020-09-10 P, Open-market purchase Athenex, Inc.ATNX 2,248,000, acquired Open Form 4 filing 0000899243-20-024976
2020-07-09 P, Open-market purchase Aldeyra Therapeutics, Inc.ALDX 13,600,000, acquired Open Form 4 filing 0000899243-20-019004
2020-06-22 P, Open-market purchase Leap Therapeutics, Inc.LPTX 3,500,000, acquired Open Form 4 filing 0000899243-20-017581
2020-06-09 P, Open-market purchase Menlo Therapeutics Inc.MNLO 4,999,999, acquired Open Form 4 filing 0000899243-20-016198
2020-05-05 P, Open-market purchase Lyra Therapeutics, Inc.LYRA 10,000,000, acquired Open Form 4 filing 0000899243-20-014580
2020-04-24 P, Open-market purchase VBI Vaccines Inc/BCVBIV 10,000,000, acquired Open Form 4 filing 0000899243-20-011371
2020-04-17 P, Open-market purchase Crinetics Pharmaceuticals, Inc.CRNX 14,999,992, acquired Open Form 4 filing 0000899243-20-010940
2020-03-19 P, Open-market purchase Adma Biologics, Inc.ADMA 1,050,000, acquired Open Form 4 filing 0000899243-20-009225
2020-03-13 P, Open-market purchase Agile Therapeutics IncAGRX 1,750,000, acquired Open Form 4 filing 0000899243-20-008589
2020-02-25 P, Open-market purchase Agile Therapeutics IncAGRX 9,000,000, acquired Open Form 4 filing 0000899243-20-005836
2020-02-11 P, Open-market purchase Adma Biologics, Inc.ADMA 15,972,950, acquired Open Form 4 filing 0000899243-20-003914
2020-02-03 P, Open-market purchase Albireo Pharma, Inc.ALBO 5,371,989, acquired Open Form 4 filing 0000899243-20-002651
2019-12-24 P, Open-market purchase Athenex, Inc.ATNX 1,060,514, acquired Open Form 4 filing 0000899243-19-030110

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, insider transactions. Retrieved 2026-08-27 from https://ebomi.com/insider/0001249675

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.